Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund I Inc GBP
|Fresenius Medical Care AG & Co. KGaA||4.49 %|
|Bristol-Myers Squibb Company||3.78 %|
|Baxter International Inc||3.74 %|
|IQVIA Holdings Inc||3.72 %|
|Stryker Corp||3.41 %|
|HCA Healthcare Inc||3.38 %|
|Immunomedics Inc||3.27 %|
|Quotient Ltd||3.25 %|
|Exelixis Inc||2.99 %|
|Bio-Rad Laboratories Inc||2.93 %|
|United States||72.70 %|
|Europe - ex Euro||7.11 %|
Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.